BR0316227A - IsÈmeros posicionais de peg ifn alfa 2a - Google Patents

IsÈmeros posicionais de peg ifn alfa 2a

Info

Publication number
BR0316227A
BR0316227A BR0316227-3A BR0316227A BR0316227A BR 0316227 A BR0316227 A BR 0316227A BR 0316227 A BR0316227 A BR 0316227A BR 0316227 A BR0316227 A BR 0316227A
Authority
BR
Brazil
Prior art keywords
positional isomers
peg ifn
ifn alfa
treatment
peg
Prior art date
Application number
BR0316227-3A
Other languages
English (en)
Inventor
Doris Brugger
Stefan Foser
Alfred Schacher
Karl Weyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0316227A publication Critical patent/BR0316227A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"ISÈMEROS POSICIONAIS DE PEG IFN ALFA 2A". A presente invenção refere-se aos isómeros posicionais interferon alfa 2a mono- pegilados, com um método para o isolamento dos mesmos e para o uso dos mesmos na fabricação de medicamentos para o tratamento de doenças, de modo especial para o tratamento de doenças viróticas.
BR0316227-3A 2002-11-15 2003-11-10 IsÈmeros posicionais de peg ifn alfa 2a BR0316227A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15
PCT/EP2003/012498 WO2004045648A1 (en) 2002-11-15 2003-11-10 Positional isomers of peg ifn alpha 2a

Publications (1)

Publication Number Publication Date
BR0316227A true BR0316227A (pt) 2005-10-04

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316227-3A BR0316227A (pt) 2002-11-15 2003-11-10 IsÈmeros posicionais de peg ifn alfa 2a

Country Status (23)

Country Link
US (1) US20040223950A1 (pt)
EP (1) EP1562634B1 (pt)
JP (1) JP4279258B2 (pt)
KR (1) KR20050065677A (pt)
CN (1) CN1323722C (pt)
AR (1) AR042039A1 (pt)
AT (1) ATE337017T1 (pt)
AU (1) AU2003293668A1 (pt)
BR (1) BR0316227A (pt)
CA (1) CA2503594C (pt)
DE (1) DE60307881T2 (pt)
ES (1) ES2270152T3 (pt)
GT (1) GT200300244A (pt)
MX (1) MXPA05005178A (pt)
NO (1) NO20052310L (pt)
PA (1) PA8587801A1 (pt)
PE (1) PE20040834A1 (pt)
PL (1) PL376883A1 (pt)
RU (1) RU2005118752A (pt)
TW (1) TW200413404A (pt)
UY (1) UY28080A1 (pt)
WO (1) WO2004045648A1 (pt)
ZA (1) ZA200503756B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2009030066A1 (fr) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JP2006508918A (ja) * 2002-09-05 2006-03-16 ザ ジェネラル ホスピタル コーポレーション 修飾されたアシアロインターフェロンおよびその使用

Also Published As

Publication number Publication date
JP2006515571A (ja) 2006-06-01
PE20040834A1 (es) 2004-11-17
PL376883A1 (pl) 2006-01-09
US20040223950A1 (en) 2004-11-11
KR20050065677A (ko) 2005-06-29
GT200300244A (es) 2004-06-03
JP4279258B2 (ja) 2009-06-17
CA2503594A1 (en) 2004-06-03
EP1562634B1 (en) 2006-08-23
DE60307881D1 (de) 2006-10-05
ZA200503756B (en) 2008-02-27
ES2270152T3 (es) 2007-04-01
EP1562634A1 (en) 2005-08-17
CA2503594C (en) 2011-05-10
WO2004045648A1 (en) 2004-06-03
MXPA05005178A (es) 2005-07-22
NO20052310D0 (no) 2005-05-11
ATE337017T1 (de) 2006-09-15
NO20052310L (no) 2005-08-09
AU2003293668A1 (en) 2004-06-15
PA8587801A1 (es) 2004-09-16
AR042039A1 (es) 2005-06-08
UY28080A1 (es) 2004-05-31
DE60307881T2 (de) 2007-03-08
CN1711109A (zh) 2005-12-21
TW200413404A (en) 2004-08-01
CN1323722C (zh) 2007-07-04
RU2005118752A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0411900A (pt) compostos antivirais e métodos
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BRPI0510654A (pt) formulações de interferon em hidrogel
SV2003001107A (es) Imidazotriazinas ref.lea 35368
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
CL2010000828A1 (es) Composicion farmaceutica que comprende un conjugado pegilado de interferon alfa y ribavirina, util en la preparacion de un medicamento para las infecciones de hepatitis c cronica.
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
ES2192839T3 (es) Timosina beta 4 oxidada.
BRPI0415249A (pt) terapia de combinação para infecção por hcv
IT9019141A0 (it) Trattamento di malattie associate ad infezioni di hiv
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação
BR0108997A (pt) Terapia imune adjuvante para hiv
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
ECSP034872A (es) Nuevos heterociclos 3
BRPI0408380A (pt) derivados 7-imino de camptotecina tendo atividade antitumoral

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/56 (2006.01), A61K 38/00 (2006.01)